Shares in Black Diamond Therapeutics will be up for grabs after the oncology biotech company said it will offer 15,000,000 shares of its common stock in a public offering. Set at a price of $5.00 per share, the company said it expects to raise $75m.
All shares being sold are by Black Diamond, with a further 2,250,000 offered to underwriters over a 30-day period. The Massachusetts, US-based company said it expects the offering to close on or around 5 July.
Go deeper with GlobalData
In 2020, Black Diamond raised approximately $231.3m from its initial public offering.
The offering comes days after the company revealed positive results for the first portion of a Phase I trial of its lead candidate BDTX-1535. The epidermal growth factor receptor MasterKey inhibitor demonstrated anti-tumour activity in non-small cell lung cancer patients. Shares in the company skyrocketed following the data, rising 126% at market open on June 27 compared to pre-announcement market close on June 26. Black Diamond Therapeutics has a current market cap of $184m.
The company has also received US Food and Drug Clearance (FDA) of an investigational new drug application for BDTX-4933 – a therapy for RAF and RAS mutant tumours – as the company ramps up its pipeline development. According to a ClinicalTrials.gov entry (NCT05786924), the Phase I trial is currently recruiting.
In a March statement announcing 2022 financial results, Black Diamond’s president and CEO David Epstein, Ph.D, hinted at a fruitful 2023.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“We expect 2023 to be a catalyst-rich year for Black Diamond following tremendous progress for our two novel MasterKey inhibitors, with BDTX-1535 continuing to advance through our Phase I clinical trial and BDTX-4933 meeting critical milestones to further progress toward the clinic,” said Epstein.
“We are driven by the clear unmet need for next-generation precision medicines to treat cancers by overcoming resistance, minimizing on-target and wild-type mediated toxicities, and addressing brain disease. We’ve designed a robust pipeline of products with brain penetration properties to address these key challenges.”
